Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Labar

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Infection|January 1, 1992
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia GroupH H Gerhartz, R Marcus, A Delmer, et al.
Bone Marrow Transplantation|May 1, 1992
Total body irradiation with or without lung shielding for allogeneic bone marrow transplantationB Labar, V Bogdanić, D Nemet, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Cyclosporin neurotoxicity in patients treated with allogeneic bone marrow transplantationB Labar, V Bogdanic, F Plavsic, et al.
Bone Marrow Transplantation|April 1, 2003
Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?P Rozman, M Karas, A Kosir, et al.
Lijecnicki Vjesnik|June 1, 1984
[Transplantation of bone marrow in the treatment of severe aplastic anemia]B Labar, V Bogdanić, A Kastelan, et al.
Annals of Hematology|April 1, 1992
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative GroupR Willemze, N van der Lely, H Zwierzina, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Experience with bone marrow transplantation for severe aplastic anemia and leukemia. Two years experience with 31 patients in Zagreb (Yugoslavia)B Labar, V Bogdanic, A Kastelan, et al.
Annals of Hematology|August 1, 1996
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-ImmunotherapyM Brugiatelli, B Holowiecka, A Dmoszynska, et al.
Journal of Chemotherapy (Florence, Italy)|December 4, 2008
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICEI Aurer, Z Mitrović, D Nemet, et al.
Annals of Hematology|March 1, 1996
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative GroupT De Witte, S Suciu, D Selleslag, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Infection|January 1, 1992
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia GroupH H Gerhartz, R Marcus, A Delmer, et al.
Bone Marrow Transplantation|May 1, 1992
Total body irradiation with or without lung shielding for allogeneic bone marrow transplantationB Labar, V Bogdanić, D Nemet, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Cyclosporin neurotoxicity in patients treated with allogeneic bone marrow transplantationB Labar, V Bogdanic, F Plavsic, et al.
Bone Marrow Transplantation|April 1, 2003
Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?P Rozman, M Karas, A Kosir, et al.
Lijecnicki Vjesnik|June 1, 1984
[Transplantation of bone marrow in the treatment of severe aplastic anemia]B Labar, V Bogdanić, A Kastelan, et al.
Annals of Hematology|April 1, 1992
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative GroupR Willemze, N van der Lely, H Zwierzina, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
Experience with bone marrow transplantation for severe aplastic anemia and leukemia. Two years experience with 31 patients in Zagreb (Yugoslavia)B Labar, V Bogdanic, A Kastelan, et al.
Annals of Hematology|August 1, 1996
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-ImmunotherapyM Brugiatelli, B Holowiecka, A Dmoszynska, et al.
Journal of Chemotherapy (Florence, Italy)|December 4, 2008
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICEI Aurer, Z Mitrović, D Nemet, et al.
Annals of Hematology|March 1, 1996
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative GroupT De Witte, S Suciu, D Selleslag, et al.
Pageof 12